NDA 215239 · Catalyst Pharms
Agamree
Vamorolone · Oral
NovelOrphanCDER novel approval, Oct 26, 2023: To treat Duchenne muscular dystrophy
Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 26, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
0 Phase 3, 1 recruiting
FAERS reports
1,745
453 serious, 32 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 22, 2026.
AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. AGAMREE is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. ( 1 )
Mechanism: Vamorolone is a corticosteroid that acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which vamorolone exerts its effect in patients with DMD is unknown.
Therapeutic areas: Neurology · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- AGAMREE · VAMOROLONE 40MG/ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vamorolone" as an intervention, any sponsor and status, largest first.
- A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)Pivotal-lookingCompleted
ReveraGen BioPharma, Inc.Industry
NCT03439670 · 121 participants · Start Jun 29, 2018 · Primary completion Feb 23, 2021
Drug: Vamorolone; Prednisone and 4 more · For: Duchenne Muscular Dystrophy
Sites: Davis, California; Los Angeles, California; Aurora, Colorado · 33 sites in all
- A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular DystrophyActive, not recruiting
Santhera PharmaceuticalsIndustry
NCT06713135 · 80 participants (planned) · Start Nov 10, 2024 · Primary completion Sep 2028
Drug: vamorolone 40 mg/mL oral suspension · For: Duchenne Muscular Dystrophy
Sites: Ghent, Belgium; Leuven, Belgium; Brno, Czechia · 18 sites in all
Santhera PharmaceuticalsIndustry
NCT05185622 · 54 participants · Start Mar 21, 2022 · Primary completion Jul 16, 2024
Drug: Vamorolone · For: Duchenne Muscular Dystrophy
Sites: Calgary, Canada; Vancouver, Canada; Ottawa, Canada · 5 sites in all
ReveraGen BioPharma, Inc.Industry
NCT02760277 · 48 participants · Start Jul 28, 2016 · Primary completion Apr 26, 2018
Drug: Vamorolone 0.25 mg/day/day; Vamorolone 0.75 mg/day/day and 2 more · For: Duchenne Muscular Dystrophy
Sites: Davis, California; Gainesville, Florida; Orlando, Florida · 12 sites in all
ReveraGen BioPharma, Inc.Industry
NCT02760264 · 48 participants · Start Jun 2016 · Primary completion May 1, 2018
Drug: Vamorolone 0.25 mg/kg/day; Vamorolone 0.75 mg/kg/day and 2 more · For: Duchenne Muscular Dystrophy
Sites: Davis, California; Gainesville, Florida; Orlando, Florida · 12 sites in all
- Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)Completed
ReveraGen BioPharma, Inc.Industry
NCT03038399 · 46 participants · Start Feb 2, 2017 · Primary completion Apr 30, 2020
Drug: Vamorolone 0.25 mg/day/day; Vamorolone 0.75 mg/day/day and 2 more · For: Duchenne Muscular Dystrophy
Sites: Davis, California; Gainesville, Florida; Orlando, Florida · 12 sites in all
ReveraGen BioPharma, Inc.Industry
NCT05166109 · 46 participants · Start Jul 7, 2022 · Primary completion Aug 18, 2025
Drug: Vamorolone; Placebo · For: Becker Muscular Dystrophy
Sites: Pittsburgh, Pennsylvania; Padova, Italy
Santhera PharmaceuticalsIndustry
NCT06649409 · 30 participants · Start Jun 5, 2024 · Primary completion Jun 29, 2024
Drug: Vamorolone; Eplerenone and 1 more · For: Pharmacodynamic
Sites: Neu-Ulm, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight increased283
- product dose omission issue120
- vomiting110
- asthenia84
- pyrexia74
- influenza72
- fatigue71
- duchenne muscular dystrophy67
- abdominal pain upper66
- increased appetite65
- diarrhoea63
- headache62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 377 |
| 2025 | 849 |
| 2026 | 514 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Agamree (Vamorolone)
2024 spending
$699K
Beneficiaries
n/a
41 claims
Per beneficiary
n/a
$97.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $698,932 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Dang UJ, Damsker JM, Guglieri M, et al. · Neurology 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Clemens PR, Perlman SJ, et al. · JAMA Neurol 2022 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK, Clemens PR, Guglieri M, et al. · JAMA Netw Open 2022 · Clinical Trial, Research Support, N.I.H., Extramural
- Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials.
de Vera A, Clemens PR, Dang UJ, et al. · Steroids 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
- Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A Systematic Review.
Pascual-Morena C, Lucerón-Lucas-Torres M, Martínez-García I, et al. · Paediatr Drugs 2024 · Systematic Review
- Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial.
Clemens PR, Berglund A, Schiava M, et al. · Neurology 2026 · Randomized Controlled Trial, Comparative Study
Sponsor: Catalyst Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.